Marrow cells of myeloid lineage from 115 patients with myelodysplastic syndrome (MDS) were characterized by multidimensional flow cytometry and compared to findings in 104 patients with various disorders and 25 normal donors. Based on phenotypic and scatter characteristics, a flow cytometric scoring system (FCSS) was developed that allowed for a simple numerical display of results. The flow cytometric scores were categorized as normal/mild (0-1), moderate (2-3) or severe (>4).
Introduction
Myelodysplastic syndromes (MDS) comprise a complex, heterogeneous group of hemopoietic stem cell disorders.
Classification and prognostic indicators include objective parameters such as cytogenetic findings, and number of cytopenias in addition to morphologic assessment of lineage dysplasias and quantification of myeloblasts. 1 Although flow cytometry is widely used for diagnosis, characterization, and classification of various hematologic malignancies and detection of posttreatment minimal residual disease, [2] [3] [4] [5] only limited data have been presented concerning diagnostic and prognostic significance of flow cytometric immunophenotyping in MDS patients. [6] [7] [8] With an understanding of normal antigenic expression during hemopoietic development as determined by multidimensional flow cytometry, the dysregulation of hemopoiesis observed in MDS could be characterized by deviations from the normal patterns. 9 Immunophenotypic abnormalities are observed on maturing cells as well as on myeloblasts. [10] [11] [12] [13] These abnormalities often affect only subpopulations of cells that co-exist with normal precursors. The characteristics and magnitude of antigenic aberrancies provide information as to the extent of dysregulation of gene products at a particular time point in the differentiation of cells as well as in the disease course.
Treatment decisions in MDS patients are generally based on disease status and the expected tempo of the disease process.
Patients with advanced disease by the criteria of the French-American-British (FAB) classification 14 and by the International Prognostic Scoring System (IPSS) 1 are often considered for early hemopoietic stem cell transplantation (SCT) if a suitable donor is identified, while patients with low risk factors initially may be observed or treated with less aggressive therapeutic modalities. 15 Therefore, patient management relies heavily upon accurate determination of disease status at the time of evaluation. The purpose of this study was to quantify and score complex flow cytometric abnormalities in a standardized, comprehensive analysis, to correlate flow cytometry scores with conventional and established parameters, and to determine the prognostic significance of flow cytometry scores for relapse, non-relapse mortality (NRM), and survival in MDS patients undergoing allogeneic SCT.
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Materials and Methods

Study Populations
Marrow aspirates from 115 patients with a diagnosis of de novo or secondary MDS based on accepted diagnostic criteria, who were referred to the Fred Hutchinson Cancer Research Center (FHCRC) for consideration of allogeneic SCT between April 1995 and December 2000, were analyzed by flow cytometry, and results were retrospectively correlated with morphologic, cytogenetic and hematologic parameters. Patient age ranged from 4 to 66 years (including 7 pediatric patients 4-16 years of age, and 108 adults more than 16 years of age); 58 were female, and 57 male. One hundred eleven of the MDS patients subsequently underwent SCT; four, for various reasons were not transplanted. Marrow aspirates were collected in sodium heparin at or near the initial examination date as part of the intake evaluation. Criteria for inclusion in the study consisted of morphologic evidence of dysplasias, abnormal peripheral blood cell counts, and clinical histories. Patients referred with an initial diagnosis of MDS who were identified as having clonal lymphoid abnormalities were excluded from the study. 3 Patients with chronic myelomonocytic leukemia (CMML) with a white blood cell count (WBC) greater than 12 x 10 9 /L were also excluded. One patient who developed MDS on a background of paroxysmal nocturnal hemoglobinuria (PNH) was included in the study.
An additional 104 patients with aplastic anemia, non-hematopoietic malignancies, and Hodgkin disease who were also referred for transplantation, and potential marrow donors who had marrow aspirates obtained because of abnormal peripheral blood cell counts were studied in comparison to MDS patients as a control cohort. Flow cytometry was also performed on marrow aliquots from 25 individuals with complete blood cell counts in the normal range at the time they served as marrow donors for transplantation. Informed consent for all research studies was obtained according to the procedures approved by the institutional review and ethics board of the FHCRC.
Morphologic Assessment of Marrow
Wright-Giemsa stained smears of marrow aspirates that had been characterized by flow cytometry were also assessed morphologically for dyserythropoiesis, megakaryocytic anomalies, dysgranulopoiesis, and myeloid hypolobulation and hypogranulation. Cases diagnosed as MDS were further sub-classified according to the FAB classification criteria 14 and the WHO system 16 (for patients referred after 1999). Complete morphologic diagnoses and flow cytometric results were available in 114 of 115 patients. The FAB classification of refractory anemia (RA) was rendered in 53 patients, refractory anemia with excess blasts (RAEB) in 30, refractory anemia with excess blasts in transformation (RAEB-t) in 15, refractory anemia with ringed sideroblasts (RARS) in 2, and CMML in 2 patients, while 9 patients were described as "unclassifiable". Three patients were given the WHO classification of refractory cytopenia with multilineage dysplasia, and a specific morphologic diagnosis was not available in one patient. Correlations between morphologic classification using FAB or WHO subtypes and flow cytometry were not attempted in this study, however, blast counts determined on the basis of morphology were separately correlated with flow findings.
A differential count was performed to ascertain percentages of myeloblasts based on total nucleated cell count. In the case of hypocellular smears from aspirates, the proportion of morphologically identified myeloblasts was obtained from B-5 formalin fixed clot sections stained with hematoxylin and eosin, and Periodic Acid Schiff.
Cytogenetic Studies
Conventional cytogenetic analysis was performed on direct and 24 to 48 hour unstimulated bone marrow cultures using standard techniques, and analyzed following trypsin Giemsa banding; 20 metaphases were evaluated.
IPSS Scoring
Prognostic scores were calculated based on marrow blast percentage, karyotype and the number of cytopenias according to the IPSS (for 113/115 patients with available cytogenetics and hematologic data). 1 The IPSS was also applied to patients with secondary MDS. Marrow blast percentages were obtained by light microscopy as described above. Cytopenias were defined as hemoglobin (Sysmex 1500 or 8000, TOA, Japan) less than 10 g/dL, absolute neutrophil count (ANC) less than 1. Table 1 ). The procedure for labeling cells has been described. CD11b  CD45   CD5  CD19  CD45   CD38  CD56  CD45   CD16  CD13  CD45   CD15  CD34  CD45   CD14  CD33  CD45   CD7  CD56  CD45 HLA-DR CD34 CD45 [20] [21] [22] Electronic gating on the basis of FSC and SSC excluded cellular debris and non-viable cells. 23 Cell population percentages were assessed by CD45 staining and SSC, as described, 18 and based on nucleated, total non-erythroid cells following NH 4 CL lysis. A cell differential was obtained by either directly gating on discrete populations identified by CD45 and SSC, or by backgating using two color antibody combinations to identify cells of interest. 18, [24] [25] [26] Boolean logic gating schemes were used for gating so that the populations of interest were electronically separated for independent analysis and also for distinguishing overlapping populations electronically. 22 Abnormalities within the maturing myeloid, monocytic, and myeloblast populations were determined on the basis of deviation from normal patterns as previously described. 21, [27] [28] [29] Cells were defined as having abnormalities when two analysts (DAW, MRL) agreed that the population was at least 0.5 decades disparate from the relative intensity of antigens expressed on corresponding normal cells. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Presence of CD7 on maturing myeloid cells and monocytes.
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Descriptions of MDS Characteristics used for Flow Cytometry Scoring:
1) Abnormal granularity
A decrease in SSC as compared to normal mature neutrophils, indicating fewer cytoplasmic granules or hypogranularity in a cell population (Fig 2) .
10,30,31
2) Abnormal decrease in CD45 expression
Coordinated increases in CD45 expression are a hallmark of normal maturation. 26 Decreased intensity of CD45 in a given population in reference to the normal lymphocytes present in a sample indicates abnormal maturation as illustrated by the abnormal myeloblast population (red) in Fig 2 D .
3) Abnormal relationships between CD11b and HLA-DR in maturing myeloid cells, monocytes or both
A characteristic acquisition of CD11b and loss of HLA-DR mark normal neutrophil development after the myeloblast stage. 27, 28 Decreases in intensities of CD11b with other immunophenotypic evidence of a left shift were considered normal findings. Abnormalities in CD11b and HLA-DR relationships lead to patterns different from normal as illustrated in
Figures 3 A and B.
4) Abnormal relationships between CD13 and CD16 in the maturing myeloid compartment
Abnormal relationships between these antigens include a "convex" pattern ( The loss of CD16 may result from genetic polymorphism 32 and is also present in PNH 33 ).
5) Expression of CD56 on maturing myeloid cells or monocytes (Figures 3 E and F)
Expression of the adhesion molecule CD56 may occur due to abnormalities in these compartments, or because of early or intense granulopoiesis following a marrow insult. 34 
6) Lack of CD33 expression on maturing myeloid cells or monocytes
The loss of CD33 is a possible antigenic aberrancy, however, it may occur as a normal variant or as a manifestation of genetic polymorphism.
35-37
7) Asynchronous shift to the left
Maturational asynchrony is detected by the expression of antigens that appear on immature cells in concert with antigens identified only on mature cells. 27 The appearance of a shift to the left within a given set of antigenic parameters that is not observed in other parameters indicates abnormal maturation. For example, as normal myeloblasts mature, CD15
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8) Presence of CD34 on maturing myeloid cells or monocytes
CD34 is an indicator of early myeloid precursors and is not observed on normal maturing myeloid cells or monocytes.
Figures 3 G and H show subpopulations of maturing myeloid cells and monocytes with dim CD34 expression.
9) Presence of lymphoid antigens on maturing myeloid cells or monocytes
In normal hematopoiesis, the gene products determining myeloid or lymphoid development have been selected correctly without improper expression of genes from other lineages. An exception is observed in abnormal cells that exhibit true lineage infidelity. 38 Usually, the aberrant lineage expression is dimmer than what is found on normal cells, similar to cases of AML that express CD7 or CD19 with less intensity of expression than the same antigens expressed on lymphoid cells.
2, 27 The expression of non-lineage antigens must be interpreted cautiously since some markers are "lineage associated"
rather than lineage specific. 39 For example, normal monocytes are positive for the T lymphoid antigen CD4. 
10) Lack of CD13, CD33, or CD14 on monocytes
The finding indicates an aberrant phenotype or maturational arrest within the monocyte compartment.
11) Presence of abnormal myeloblasts
Criteria such as percentage of CD34 positive cells, position by CD45 and SSC, and presence/absence of myeloid antigens were taken into consideration when defining a myeloblast. Normal myeloblasts identified by the heterogeneous expression of CD34 also exhibit HLA-DR, CD13, and CD33 at high levels, but do not express other markers of mature neutrophils such as CD11b, CD15 and CD16. Normal myeloblasts are intermediate in size by FSC but have low SSC. The progression to promyelocytes is denoted by the loss of CD34 and HLA-DR expression, acquisition of high levels of CD15, and a marked increase in SSC, but without expression of CD11b. 9 Table 2 lists examples of abnormalities observed in myeloblast populations in marrows from patients with MDS. Many marrows had myeloblasts showing more than one of these abnormalities.
12) Increased lymphoid to myeloid ratio
Determination of absolute counts of cells in marrow is not possible. The relative proportion of lymphocytes to myeloid cells, however, can be used to identify abnormally low proportions of myeloid cells. An increased proportion of lymphoid cells to myeloid cells in this patient population is generally indicative of a decrease in myelopoiesis. 
Flow Cytometric Scoring System (FCSS)
A FCSS was devised as a means of condensing multiple flow cytometric abnormalities into numerical scores (Table 3) . Scores were calculated based on types of abnormalities in the maturing myeloid cells and monocytes, flow cytometric blast counts, and degree of impaired myelopoiesis based on lymphoid to myeloid ratio. Additional weight was given to marrows showing lineage infidelity (presence of lymphoid antigens on myeloid or monocytic cells) or marked maturational asynchrony as evidenced by CD34 expression on maturing myeloid cells or monocytes. These two abnormalities are believed to result from significant genetic dysregulation. Scores were calculated on marrow samples obtained at initial (pre transplant) examination of the patient.
Scores for abnormalities in maturing myeloid cells and monocytes were generated as follows: One additional point was given if myeloblasts were less than 5% but clearly abnormal. Two additional points for 5-10% abnormal myeloblasts, 3 points for 11-20%, and 4 points for 21-30%. One point was also given if the lymphoid to myeloid ratio was 1.0 or greater (there were no patients with more than 5% myeloblasts that had phenotypically normal myeloblasts).
The total flow score comprised the sum of all abnormalities observed for a patient at a specific time point. Total scores reflecting the degree of flow cytometric aberrancies were grouped into the following categories: 0-1 = normal/mild; 2-3 = moderate; 4-9 = severe. Patient samples were evaluated and scored by two authors (DW, ML) blinded to additional clinical information about the patient.
For 
Transplantation
Among the 111 patients who received allogeneic SCT, 89 were conditioned with oral busulfan (prescribed dose 1 mg per kg every 6 hours for 16 doses on days -7 through -4; busulfan doses were adjusted to achieve steady state plasma concentrations of 800-900 ng/mL) followed by intravenous cyclophosphamide (60 mg per kg on days -3 and -2). Seven patients were conditioned with cyclophosphamide, 2 x 60 mg/kg intravenously and fractionated total body irradiation (TBI) for total doses of 800-1320 cGy, nine received oral busulfan, 0.44 mg/kg for 16 doses, followed by 6 x 200 fractionated TBI, and the remaining 6 patients received miscellaneous regimens. Marrow (n = 82) or peripheral blood stem cells (n = 29) were infused intravenously after completion of TBI, or within 36-48 hours of the last dose of cyclophosphamide. Cyclosporine and methotrexate were
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given as graft versus host disease (GVHD) prophylaxis. Engraftment, and acute and chronic GVHD were assessed by established criteria, as described previously. [40] [41] [42] GVHD was treated with corticosteroids, monoclonal antibodies, cyclosporine, mycophenolate mofetil, tacrolimus, or combinations of these agents. Details of the long-term follow-up program have been reported recently.
43
Statistics
Correlation between continuously valued quantities such as flow score and hematologic parameters was evaluated using Spearman's rank correlation coefficient. Flow scores and blast counts were compared between two groups using two-sided
Wilcoxon rank sum tests. Trends across ordered groups were evaluated using a non-parametric test for trend. 44 Proportions were compared between groups using either a chi-square test or Fisher's exact test. Flow score was treated as a continuous valued diagnostic test for which the accuracy parameters sensitivity and specificity were calculated. Sensitivity was evaluated among MDS patients and is defined as the proportion of patients with a flow score above a specified cut-point for positivity (true positive rate). Specificity was evaluated among patients with a diagnosis other than MDS and defined as the proportion of subjects with a flow score below a certain criterion for positivity (also known as the true negative rate). Sensitivity and specificity are reported for a range of cut-off values for the flow score in order to provide information about the trade-offs in these quantities as the cut-off is shifted. Proportion correctly classified was the proportion of subjects with true positive or true negative values at the specified cutpoint.
Survival curves were calculated using the method of Kaplan and Meier (K-M). 45 Incidence of relapse, GVHD, and NRM were evaluated using cumulative incidence methodology with death or relapse treated as competing risk events where appropriate. 46 Comparisons between time to event curves were made using a log-rank test. Cox proportional hazards regression was performed to assess the relative impact of flow score and components of the IPSS score on survival, relapse and non-relapse For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
Results
Myeloid and Monocytic Dyspoiesis in MDS Compared to Control Groups
Among 115 MDS patients studied, 90 (78%) had abnormalities in either the myeloid or monocytic compartment or both, alone or combined with the presence of phenotypically abnormal myeloblasts that ranged from 0.6% to 58% (Table 4) . In four patients, the disease was originally classified as MDS by the referring institutions but had progressed to more than 30% myeloblasts (thus qualifying as acute myelogenous leukemia by the FAB criteria 16 ) by the time they were evaluated at the FHCRC. These patients were retained in the study. The most common abnormality in marrows from MDS patients was the presence of phenotypically abnormal myeloblasts (62%). In 27 of the 115 MDS patients (23%), phenotypically abnormal myeloblasts were present at less than 5% of total non-erythroid cells. The most common phenotypic aberrancies in maturing myeloid cells and monocytes were in the abnormal relationship between CD13 and CD16 in myeloid cells (23%), asynchronous shifts to the left (23%), and presence of CD56 on maturing myeloid cells (16%) and monocytes (17%). Seventy-nine patients (69%) had more than one abnormality.
Flow cytometric results in patients with MDS were compared to those in 25 normal donors. None of the 25 normal donors had abnormal myeloid, monocytic, or myeloblast findings. The frequencies of flow cytometric myeloid and monocytic abnormalities in patients with previously diagnosed MDS were then compared to results in 104 patients who, as described above, had either received chemotherapy or patients who exhibited peripheral blood cytopenias and were evaluated to rule out marrow disorders. Although some flow cytometric abnormalities were detected in this group, aberrant findings were significantly less frequent than in MDS patients ( Table 4 : Myeloid and monocytic dyspoiesis detected by flow cytometry *Number of abnormalities are significantly lower than MDS patients (P-value of a two-sided Fisher's exact test < 0.05) **Number of abnormalities is significantly higher than MDS patients (P-value of a two-sided Fisher's exact test < 0.05) One patient missing cytogenetic data Flow cytometry scores based on the above findings for the 115 MDS patients were compared to the scores determined for the 104 control cohort patients. Various score levels were used as cut-offs to distinguish between these two groups of patients
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From (Table 5) . Fifty-five percent of MDS patients had flow scores of 3 or greater, while none of the control patients did, i.e., a flow score of 3 or more allowed for a specificity of 100% with 55% sensitivity. A flow score of 2 or more resulted in 93% specificity with 70% sensitivity. Table 5 : Sensitivity and specificity for flow cytometric scores among MDS patients and the non-MDS cohort.
Flow Cytometry Scores and IPSS
In 113 pre-transplant patients with complete laboratory and cytogenetic data, the correlation between flow and IPSS scores was evaluated. A Spearman coefficient for the two scores was 0.64, indicating a strong correlation between the two measures.
Scores based on flow cytometric data significantly increased with increasing IPSS scores (p < 0.01), Table 6 . In addition, individual components of the IPSS score were compared with flow scores. As expected, the percentage of myeloblasts, as determined by flow cytometry, also increased with increasing IPSS scores (p<0.01). White blood cell counts and ANC values were available in 114 patients ( Table 7) . As the flow cytometry score increased, WBC and ANC decreased (p<0.01), suggesting that higher flow scores correlated with ineffective granulopoiesis. Correlations with hemoglobin and platelet counts were not attempted since the majority of patients had received multiple red blood cell and platelet transfusions prior to evaluation. Since absolute counts of cells in marrow aspirates cannot be directly determined, the ratio of lymphoid to myeloid cells was used as a means of assessing inadequate myelopoiesis. The lymphoid to myeloid ratio also showed a high negative correlation with both ANC and WBC as indicated by significant Spearman Correlation Coefficients (-0.60 and -0.56, respectively; p < 0.001). For
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Flow cytometric analysis calculated blasts as a percentage of total non-erythroid cells (erythrocytes were lysed by NH 4 Cl), while morphologic counts used total nucleated cells as the denominator. Thus, flow cytometric myeloblast percentages were expected to be higher than those derived from morphology. However, flow cytometric myeloblast counts were often lower than the morphologic blast counts reported by the pathologist. Conceivably, hypogranular promyelocytes or other abnormally maturing myeloid cells may be included in the blast count by light microscopy. Twenty-seven patients were identified by flow cytometry as having abnormal myeloblasts at less than 5%. Nineteen of these marrows were not identified as abnormal by microscopic examination.
Flow Cytometry Score and Outcome after Transplantation
One hundred-and eleven patients underwent allogeneic SCT. Flow cytometry was evaluated a median of 21 (range = 1-124) days prior to SCT. At a median follow-up of 4 (range = 1.1-6.5) years, 59 patients were alive. Fifty-two died at a median of 5.8 (range = 0.4-52.5) months after SCT. The 5-year overall survival (OS) was 49% for the entire group, 53% for patients with idiopathic MDS, 26% for patients with secondary MDS, and 50% for patients with predisposing hematological disease (p = 0.08). Nineteen patients had disease recurrence for a cumulative relapse incidence of 18% (idiopathic MDS = 15%, secondary MDS = 33%, predisposing disease = 20%, p = 0.10). There were no significant differences with regard to NRM, acute (grade II-IV) or chronic GVHD.
Post-transplant outcome was analyzed on the basis of pre-transplant flow cytometry scores categorized into mild, moderate, and severe. As shown in Figure 4A , the cumulative incidences of relapse at 5-years were 3%, 15% and 33%, respectively (p < 0.01). The corresponding numbers for overall survival were 74%, 40% and 36%, respectively (p < 0.01) ( Figure 4B ). When patients with secondary MDS and predisposing hematological disease (n = 26) were excluded, the relapse incidences were 0.0%, 13%, and 28% respectively for the three flow score groups (p = 0.01). The incidence of NRM was marginally associated with flow scores (p = 0.06), mainly due to a significant difference between mild and moderate groups. Acute and chronic GVHD did not significantly correlate with flow scores.
For As indicated above, the percentage of myeloblasts, as determined by flow cytometry, also increased with increasing IPSS scores (p<0.01). However, since blast count is included in both the flow cytometric score and IPSS score, the correlation observed may be a result of enumeration of blasts in the two systems. Flow cytometry can evaluate whether myeloblasts are normal or phenotypically aberrant, and adding information beyond myeloblast percentage may be of prognostic value in addition to conventional parameters. The flow score was modified in an analysis so that 2 points were given to all patients when myeloblasts were abnormal, rather than adding points on the basis of percentage of myeloblasts (in order to avoid having percent blasts in both the flow score and the IPSS). An additional multivariate Cox regression using the adjusted flow score showed similar results. Survival, relapse, and non-relapse mortality by flow score remained significant (p<0.01, p = 0.03, and p = 0.03), cytogenetics was also still significant (p <0.01 for both), while morphologic blasts and cytopenias were not significant.
A comparison of flow cytometric score with IPSS scores shows that among the 12 patients with low risk IPSS scores, 11 had flow scores in the mild or moderate category. Only one patient within the IPSS low risk group was severe by flow score ( Table   9 ). None of these patients relapsed post transplant. Conversely, there were no patients with low flow scores within the IPSS high risk group. Table 9 : Cross Tabulation of IPSS category and flow score Figure 5A shows the incidence curves for probability of relapse by IPSS category. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
Discussion
The appearance of cell surface antigens on normal hemopoietic cells is a highly regulated and coordinated process that may be altered in hemopoietic diseases. 9, 20, 21, [26] [27] [28] [29] 48 Myelodysplastic syndromes comprise a rather heterogeneous spectrum of disorders, and several studies have shown a variety of aberrant antigen expression [6] [7] [8] [10] [11] [12] [13] . In the present study we attempted to capture abnormal parameters determined by multidimensional flow cytometry into a FCSS in order to measure "distance from normal". As observed with aberrant antigen expression in acute leukemias, the abnormalities detected in MDS patients were different from individual to individual prompting a scoring system based on the sum of the abnormalities rather than focusing on individual antigenic differences 2, 38, 48 . The scoring system tested the components of myeloid maturation separately; blasts, monocytes, and neutrophils. The measure of phenotypic abnormalities on the maturing myeloid, monocytoid as well as blasts showed a high correlation to IPSS scores. Moreover, in patients with MDS who underwent allogeneic SCT, the flow scores used to measure abnormal antigen expression correlated with post-transplant outcome.
Flow cytometric analysis confirmed that a large proportion of MDS marrows had myeloid, monocytic, and myeloblast characteristics divergent from normal, and significantly different from findings in patients with other marrow diseases. In the proposed flow scoring system, scores of 3 or greater completely distinguished MDS patients from controls, and flow scores of 2 or greater were significantly correlated with a diagnosis of MDS. While no abnormalities were observed in marrows from normal donors, single abnormalities were occasionally observed in patients with other diseases, particularly after chemotherapy.
In such cases the marrow showed increased myelopoiesis, associated with single flow aberrancies. These data suggest that flow scores are useful to distinguish true myeloid dyspoiesis from chemotherapy effects, and aplastic anemia from MDS. 49 Additional studies comparing results in patients with MDS to patients with other marrow diseases may further refine flow cytometric features as diagnostic parameters for MDS.
Patients with complex cytogenetic abnormalities showed extensive flow cytometric aberrancies and increased proportions of phenotypically abnormal myeloblasts. Conversely, patients with favorable karyotypes (using IPSS criteria) were more likely to have low flow scores, although several patients with favorable cytogenetics, including a normal karyotype, had marked flow
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From cytometric abnormalities and increased flow scores. Therefore, flow cytometric analysis may be especially useful for risk assessment of MDS in patients with normal cytogenetics with minimal dysplastic changes by light microscopy and with low blast cell counts. Objective flow cytometric scoring in a larger data set may also be useful for following patients over time and in patients with syndromes overlapping with MDS such as myeloproliferative syndromes, HIV cytopenias, hypoplastic anemias and AML with low blast cell counts.
Antigenic abnormalities observed on dysplastic maturing myeloid, monocytic, and myeloblastic cells are biologic signals of abnormal maturation. The present data suggest that myeloid abnormalities become more prominent as the disease progresses.
The data also indicate that these abnormalities have prognostic significance for outcome after allogeneic SCT. The probability of post-transplant relapse increased significantly with increasing flow scores, and the probability of survival declined. While not surprising in patients who also had a poor risk karyotype, 42 the correlation was observed for all patients. While karyotype remains a major prognostic factor for survival and relapse, a flow score that measures the dysplastic features of the myeloid series was shown to have a stronger impact than morphologic blast count or cytopenias in a multivariate analysis. The data also support that flow cytometric scoring may further separate individual patients with respect to risk of relapse in a larger data set that includes higher numbers of patients in each of the IPSS categories.
The flow cytometric analysis described here was restricted to the study of maturing myeloid cells, monocytes, and myeloblasts with specific, uniform combinations of myeloid and lymphoid antibodies. While various antibody combinations are useful to study cellular immunophenotypes in MDS by flow cytometry, 11, 12, 49 the consistent use of a precise panel of 13 antibodies generated a database that allowed for the development of a scoring system. Analysis of the erythroid and megakaryocytic compartments were not included in this analysis for several reasons. For cells of erythroid lineage, the panel of available antibodies is too limited to evaluate maturational irregularities. However, considering the fact that anemia often is the presenting and most prominent feature in patients with MDS, efforts should be directed at expanding our abilities to phenotypically characterize the erythroid compartment. In regards to megakaryocytes, difficulties are mostly technical in nature. Because of their low frequency, large size, propensity to clump, and the complicated pre-analytical techniques involved, megakaryocytes are currently not amenable to routine flow cytometric analysis. 50 In addition, platelet adhesion to other cells such as monocytes may lead to incorrect identification of megakaryocytes. 51 Finally, while it may be possible to
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In summary, the flow scoring system proposed here correlated with the established IPSS, and on its own was of prognostic significance (p < 0.01) in patients undergoing allogeneic SCT. The identification of myeloid or monocytic dyspoiesis and abnormal immunophenotypes of myeloblasts in patients with MDS by flow cytometry may add prognostic significance beyond that obtained by morphology and cytopenias. Future studies could conceivably combine and integrate multidimensional flow cytometric analyses with other parameters of MDS to further prognostic accuracy.
